Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Medicine

Immunology

Internal Medicine

Infectious Diseases

Animal Science And Zoology

Show all topics

DOI

10.1016/s1473-3099(24)00421-3